There are 4 EBV latency states in B cells. Type III latency is the most immunogenic with expression of all of the latency-associated proteins that induce B-cell transformation and is seen in lymphomas that arise in individuals with profound immunosuppression such as PTLD. Type II latency tumors that include some cases of Hodgkin lymphoma and some NHLs express EBNA1, LMP1, and LMP2 and have intermediate immunogenicity. BL expresses type I latency with only EBNA1 expressed and is poorly susceptible to an EBV-CTL response. In type 0 latency, seen in normal memory B cells, no viral genes are expressed. Dalton et al show that incubation of type I latency lymphoma cells with decitabine can result in upregulation of the LMP1 and EBNA2 genes, making these cells more susceptible to EBV-CTLs. NK-T, natural killer T cell.